A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

April 29, 2016

Primary Completion Date

October 18, 2017

Study Completion Date

October 18, 2017

Conditions
Presbyopia
Interventions
DRUG

AGN-199201 ophthalmic solution

1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

DRUG

AGN-190584 ophthalmic solution

1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

DRUG

AGN-190584 vehicle

Vehicle to AGN-190584

DRUG

AGN-199201 + AGN-190584 Combination

1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.

DRUG

AGN-199201 vehicle

Vehicle to AGN-199201

Trial Locations (20)

16066

Scott & Christie and Associates, PC, Cranberry Township

21210

Specialized Eye Care, Baltimore

30260

Clayton Eye Center, Morrow

32757

Mid Florida Eye Center, Mt. Dora

38119

Total Eye Care, PA, Memphis

44141

Cleveland Eye Clinic, Brecksville

46260

Price Vision Group, Indianapolis

53142

The Eye Centers of Racine & Kenosha, Kenosha

63090

Comprehensive Eye Care, Ltd, Washington

78240

Medical Center Ophthalmology Associates, San Antonio

79902

Cataract and Glaucoma Center, El Paso

80120

Corneal Consultants of Colorado, P.C., Littleton

84020

Hoopes Durrie Rivera Research, LLC, Draper

90701

Sall Research Medical Center, Artesia

91702

Milton M. Hom, OD, FAAO, Azusa

92115

West Coast Eye Care, San Diego

92626

WCCT Global, LLC, Costa Mesa

92663

The Eye Research Foundation, Newport Beach

94954

North Bay Eye Associates, Inc., Petaluma

95670

Martel Eye Medical Group, Rancho Cordova

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY